Advanced Development of OXOS X3, a Point-of-Care Diagnostic X-Ray Imaging System for Detection of Fracture and other Trauma
Health and Human Services (all) · BARDA - ASPR / DAAPPO / BARDA DCMA
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75A50126C00011 in this department, oldest first.
- Sep 29, 2026 · this noticeSpecial Notice
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
Transform trauma response by bringing hospital-grade imaging directly to the point of need by developing and receiving FDA clearance of the OXOS X3, an ultra-portable, high-output general radiography and fluoroscopy system engineered to function as a threatagnostic medical countermeasure (MCM). Designed to weigh under 25 pounds and deliver up to 100 kV / 15 mA at the point of need, X3 augments the transport-to-imaging bottleneck that currently degrades survival in mass casualty incidents (MCIs) involving nuclear detonation, conventional blast, or large-scale trauma surge events. By bringing ho… (show all)
spital-grade diagnostic capability directly to the casualty, whether in a high-volume Emergency Department, a temporary field hospital, or a triage site, X3 restores the diagnostic foundation of the ATLS primary survey at every step where current portable assets fail.
Who won similar work
5 award notices on SAM.gov in the last 24 months. Matched by: Same office (BARDA - ASPR / DAAPPO / BARDA DCMA), same product/service code (PSC) AN13 and NAICS 541714.
Single-winner award sizes (5): middle half $98.6M to $186.0M, median $99.7M; range $7.5M to $339.2M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| CIDARA THERAPEUTICS INC | 1 | $339.2M | Oct 14, 2025 |
| RAFA LABORATORIES LTD | 1 | $186.0M | Oct 1, 2025 |
| Flosonics Medical LLC | 1 | $99.7M | Jun 5, 2026 |
| OSIVAX Paris 8 �le-de-France 75008 FRA | 1 | $98.6M | Oct 14, 2025 |
| ISOLA THERAPEUTICS INC | 1 | $7.5M | Apr 27, 2026 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- Jun 5, 2026Flosonics Medical LLC$99.7MBiomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)No listed company matched (Materiality N/A)
- Apr 27, 2026ISOLA THERAPEUTICS INC$7.5MBARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)No listed company matched (Materiality N/A)
- Oct 14, 2025OSIVAX Paris 8 �le-de-France 75008 FRA$98.6MClinical Proof of Concept of OVX836, a single-shot broadly protective Influenza A vaccine for immediate protection against emerging pandemic strainsNo listed company matched (Materiality N/A)
- Oct 14, 2025CIDARA THERAPEUTICS INC$339.2MDevelopment of CD388 as a long-lasting prophylactic anti-viral option for protection against the health impacts caused by influenzaNo listed company matched (Materiality N/A)
- Oct 1, 2025RAFA LABORATORIES LTD$186.0MDevelopment Of a Concentrated Tranexamic Acid (TXA) Intramuscular InjectionNo listed company matched (Materiality N/A)
Competitive landscape
For the 5 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Health & Human Services, Dept of (HHS) since 2024 (3 filings)
- 0 of their lobbyists list a past Health & Human Services, Dept of (HHS) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 252 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.